[ad_1]
New York, December 3, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announced the release of the report “Migraine-Global Drug Forecast and Market Analysis in 2030”- https://www.reportlinker.com/p06188323/?utm_source=GNW
In most cases, migraine is related to symptoms such as photophobia, sound photophobia, photophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.
The two clinically and commercially relevant sections considered for the classification of migraines in this report are patients with episodic migraine, with a maximum of 14 migraines per month, and patients with chronic migraine, with 15 or more episodes per month.
For patients who experience four or more migraine attacks per month, doctors hope to prescribe preventive treatment. Preventive treatment is considered to be a supplement to acute treatment to minimize the risk of headaches from overuse of drugs associated with non-steroidal anti-inflammatory drugs (NSAID) and triptan therapy.
The value of 7MM’s migraine market in the base year of 2020 is $4.7B. Analysts predict that during the 10-year forecast period, the market is expected to grow at a compound annual growth rate (CAGR) of 9.9%, reaching $12.0B by 2030. The main drivers of this growth will be calcitonin prescription increase gene-related peptide (CGRP) antagonists, gepants and monoclonal antibodies (mAbs). In addition, the launch of five new pipeline products will have a higher annual treatment cost (ACOT) compared with the cost of the most commonly used migraine…
The full story can be found on Benzinga.com
[ad_2]
Source link
